Naftin® Gel, 1% contains the synthetic, broad-spectrum, antifungal agent naftifine hydrochloride. Naftin® Gel, 1% is for topical use only.
Chemical Name
(E)-N-Cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride.
Naftifine hydrochloride has an empirical formula of C21H21N•HCl and a molecular weight of 323.86.
Contains
| Active Ingredient | |
| Naftifine hydrochloride | 1% |
Inactive Ingredients
polysorbate 80, carbomer 934P, diisopropanolamine, edetate disodium, alcohol (52%v/v) and purified water.
Naftin Gel - Clinical Pharmacology
Naftifine hydrochloride is a synthetic allylamine derivative. The following in vitro data are available, but their clinical significance is unknown. Naftifine hydrochloride has been shown to exhibit fungicidal activity in vitro against a broad spectrum of organisms, including Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Epidermophyton floccosum, Microsporum canis, Microsporum audouini, and Microsporum gypseum; and fungistatic activity against Candida species, including Candida albicans. Naftin® Gel, 1% has only been shown to be clinically effective against the disease entities listed in the INDICATIONS AND USAGE section.
Although the exact mechanism of action against fungi is not known, naftifine hydrochloride appears to interfere with sterol biosynthesis by inhibiting the enzyme squalene 2, 3-epoxidase. This inhibition of enzyme activity results in decreased amounts of sterols, especially ergosterol, and a corresponding accumulation of squalene in the cells.
Pharmacokinetics
In vitro and in vivo bioavailability studies have demonstrated that naftifine penetrates the stratum corneum in sufficient concentration to inhibit the growth of dermatophytes.
Following single topical applications of 3H-labeled naftifine gel 1% to the skin of healthy subjects, up to 4.2% of the applied dose was absorbed. Naftifine and/or its metabolites are excreted via the urine and feces with a half-life of approximately two to three days.
Indications and Usage for Naftin Gel
Naftin® Gel, 1% is indicated for the topical treatment of tinea pedis, tinea cruris and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans1 and Epidermophyton floccosum.1
- 1
- Efficacy for this organism in this organ system was studied in fewer than 10 infections.
Contraindications
Naftin® Gel, 1% is contraindicated in individuals who have shown hypersensitivity to any of its components.
Warnings
Naftin® Gel, 1% is for topical use only and not for ophthalmic use.
Precautions
General
Naftin® Gel, 1% is for external use only. If irritation or sensitivity develops with the use of Naftin® Gel, 1%, treatment should be discontinued and appropriate therapy instituted. Diagnosis of the disease should be confirmed either by direct microscopic examination of a mounting of infected tissue in a solution of potassium hydroxide or by culture on an appropriate medium.
Information for patients
The patient should be told to:
- Avoid the use of occlusive dressings or wrappings unless otherwise directed by the physician.
- Keep Naftin® Gel, 1% away from the eyes, nose, mouth and other mucous membranes.
Carcinogenesis, mutagenesis, impairment of fertility
Long-term studies to evaluate the carcinogenic potential of Naftin® Gel, 1% have not been performed. In vitro and animal studies have not demonstrated any mutagenic effect or effect on fertility.
Pregnancy
Teratogenic Effects
Pregnancy Category B
Reproduction studies have been performed in rats and rabbits (via oral administration) at doses 150 times or more than the topical human dose and have revealed no evidence of impaired fertility or harm to the fetus due to naftifine. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Nursing mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Naftin® Gel, 1% is administered to a nursing woman.
Pediatric use
Safety and effectiveness in pediatric patients have not been established.
Adverse Reactions
During clinical trials with Naftin® Gel, 1%, the incidence of adverse reactions was as follows: burning/stinging (5.0%), itching (1.0%), erythema (0.5%), rash (0.5%), skin tenderness (0.5%).
Naftin Gel Dosage and Administration
A sufficient quantity of Naftin® Gel, 1% should be gently massaged into the affected and surrounding skin areas twice a day in the morning and evening. The hands should be washed after application.
If no clinical improvement is seen after four weeks of treatment with Naftin® Gel, 1%, the patient should be re-evaluated.
How is Naftin Gel Supplied
Naftin® (naftifine hydrochloride) 1% Gel is supplied in collapsible tubes in the following sizes:
| 40g – NDC 0259-4770-40 |
| 60g – NDC 0259-4770-60 |
| 90g -- NDC 0259-4770-90 |
Note: Store at room temperature.
Manufactured for: Merz Pharmaceuticals, Greensboro, NC 27410
5011343
© 2009 Merz Pharmaceuticals
Rev 2/09 Printed in U.S.A.
PRINCIPAL DISPLAY PANEL - 40g Carton
NDC 0259-4770-40
NAFTIN®
40g gel
NAFTIFINE HCl 1% GEL
Rx Only
MERZ®
| NAFTIN naftifine hydrochloride gel | ||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||
| Marketing Information | |||
| Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA | NDA019356 | 10/01/1990 | |
| Labeler - Merz Pharmaceuticals, LLC (126209282) |
More Naftin Gel resources
- Naftin Gel Side Effects (in more detail)
- Naftin Gel Use in Pregnancy & Breastfeeding
- Naftin Gel Support Group
- 2 Reviews for Naftin - Add your own review/rating
Compare Naftin Gel with other medications
- Tinea Corporis
- Tinea Cruris
- Tinea Pedis
No comments:
Post a Comment